EUVIMEDEUVIMED entdecken
Editorial

Overcoming barriers to unlock the therapeutic potential of saroglitazar for the management of metabolic dysfunction-associated steatotic liver disease

Murali Krishna Moka, Deepalaxmi Rathakrishnan, D K Sriram, Melvin George

Clinical Nutrition · 2025

DOI: 10.1016/j.clnu.2025.03.024 ↗

Kurz gefasst

Editorial in der Zeitschrift Clinical Nutrition, 2025. Verfasst von Murali Krishna Moka und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research, Hindu Mission Hospital, Tambaram, Chennai, 600045, Tamil Nadu, India. Hauptthemen laut MEDLINE: Fatty Liver, Metabolic Diseases, Non-alcoholic Fatty Liver Disease, Phenylpropionates. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty LiverMetabolic DiseasesNon-alcoholic Fatty Liver DiseasePhenylpropionatesPyrrolesHumansLipid MetabolismPPAR alphaPPAR gamma

Stichwörter der Autor:innen

EffectivenessMetabolic dysfunction-associated steatohepatitis (MASH)Metabolic dysfunction-associated steatotic liver disease (MASLD)Non-alcoholic fatty liver disease (NAFLD)Peroxisome proliferator-activated receptorSaroglitazar

Substanzen

PhenylpropionatesPPAR alphaPPAR gammaPyrrolessaroglitazar

Autor:innen und Institutionen

  • Department of Clinical Research, Hindu Mission Hospital, Tambaram, Chennai, 600045, Tamil Nadu, India.
  • Department of Diabetology and Endocrinology, Hindu Mission Hospital, Tambaram, Chennai, 600045, Tamil Nadu, India.
  • Department of Clinical Research, Hindu Mission Hospital, Tambaram, Chennai, 600045, Tamil Nadu, India. Electronic address: drmelvingeorge@hindumissionhospital.org.

Zitieren

APA

Moka, M. K., Rathakrishnan, D., Sriram, D. K., & George, M. (2025). Overcoming barriers to unlock the therapeutic potential of saroglitazar for the management of metabolic dysfunction-associated steatotic liver disease. Clinical Nutrition. https://doi.org/10.1016/j.clnu.2025.03.024

Vancouver

Moka MK, Rathakrishnan D, Sriram DK, George M. Overcoming barriers to unlock the therapeutic potential of saroglitazar for the management of metabolic dysfunction-associated steatotic liver disease. Clinical Nutrition. 2025. doi:10.1016/j.clnu.2025.03.024

BibTeX
@article{Moka2025,
  author = {Moka, Murali Krishna and Rathakrishnan, Deepalaxmi and Sriram, D K and George, Melvin},
  title = {Overcoming barriers to unlock the therapeutic potential of saroglitazar for the management of metabolic dysfunction-associated steatotic liver disease},
  journal = {Clinical Nutrition},
  year = {2025},
  doi = {10.1016/j.clnu.2025.03.024}
}
Kostenlos starten →